SWM
REGN icon

Selective Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Selective Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-50
Closed -$35K – 820
2022
Q1 		$35K Sell
50
-250
-83% -$158K 0.01% 365
2021
Q4 		$189K Buy
300
+50
+20% +$30.7K 0.08% 126
2021
Q3 		$151K Buy
+250
New +$155K 0.08% 130

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Selective Wealth Management's REGN Position: Q2 2022 in Review

Selective Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q2 2022, closing a stake of 50 shares — an estimated $35K sold.

Selective Wealth Management first reported a position in REGN in Q3 2021 and held it in 3 quarters. The position peaked at $189K in Q4 2021. 1,064 funds tracked by Wall St. Rank hold REGN as of Q2 2022.

  • Selective Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Selective Wealth Management sold 50 Regeneron Pharmaceuticals shares in Q2 2022, an estimated $35K.
  • Selective Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2021 and held it in 3 quarters.
  • Selective Wealth Management's Regeneron Pharmaceuticals position peaked at $189K in Q4 2021.
  • 1,064 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2022.

Based on Selective Wealth Management's 13F filing for Q2 2022, filed 28 Jul 2022.